Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice

• Published in: Life sciences (1973) 2020-11, Vol.261, p.118457, Article 118457
• Main Authors: Liu, Qian, Cai, Bei-yu, Zhu, Li-xin, Xin, Xin, Wang, Xin, An, Zi-ming, Li, Shuang, Hu, Yi-yang, Feng, Qin
• Format: Article
• Language: English
• Subjects: Abundance; Alanine; Alanine transaminase; Blood; Blood glucose; Diabetes mellitus; Digestive system; Fasting; Fatty liver; Gastrointestinal tract; Gene sequencing; Glucagon; Glucagon-like peptide 1; Glucagon-like peptide-1(GLP-1); Glucose; Glucose metabolism; Gut microbiome; Histopathology; Inflammation; Insulin; Insulin resistance; Intestinal microflora; Intestine; Klebsiella; Lachnospiraceae; Lactulose; Lipids; Liraglutide; Liver; Liver diseases; Low density lipoprotein; Metabolism; Microbial community diversity; Microbiomes; Microorganisms; Nonalcoholic fatty liver; Rodents; rRNA 16S; Steatosis; Triglycerides
• ISSN: 0024-3205; 1879-0631
• DOI: 10.1016/j.lfs.2020.118457

Liraglutide, a glucagon-like peptide-1(GLP-1) analog, is effective for the treatment of type II diabetes and nonalcoholic fatty liver disease (NAFLD). It was proved that gut microbiome plays a role in the development of NAFLD. This study aims to observe the therapeutic effect of liraglutide on nonalcoholic fatty liver (NAFL) in mice and effect on the gut microbial community. The db/db mice were used as the NAFL model, and lactulose was used as the positive control drug. Hepatic triglyceride, liver histopathology, and indices of glucolipid metabolism, including fasting blood glucose, fasting insulin, insulin resistance index and blood lipids were evaluated after treatment of liraglutide or lactulose for four weeks. The colonic microbiome of the mice was analyzed by 16S rRNA gene sequencing. Liraglutide significantly reduced the hepatic triglyceride (TG) content, alanine aminotransferase (ALT) activity, fasting blood glucose, insulin resistance and serum low density lipoprotein (LDL) in the db/db mice. In terms of hepatic pathologies, hepatic steatosis was significantly improved after liraglutide treating. Microbiome analysis revealed that liraglutide significantly increased the abundance of Akkermansia, Romboutsia, norank_f_Bacteroidales_S24-7_group, and decreased the abundance of Klebsiella, Anaerotruncus, Bacteroides, Lachnospiraceae_UCG-001, Lachnospiraceae_NK4A136_group, Ruminiclostridium, uncultured_f__Ruminococcaceae, and Desulfovibrio. The results of the present study suggested that liraglutide had a certain therapeutic effect on fatty liver in db/db mice and had an impact on the composition of the intestinal microflora, especially some bacteria related to glucolipid metabolism and intestinal inflammation. Affecting gut microbiome might be a potential mechanism of liraglutide in treating NAFL.